Abstract / Description: 

Atherosclerotic cardiovascular disease remains a major cause of death and disability, especially for high-risk familial hypercholesterolemia individuals. PCSK9i (proprotein convertase subtilisin kexin type 9 inhibitors) reduce low-density lipoprotein cholesterol levels and cardiovascular event rates. However, PCSK9i prescriptions are rejected at high rates by payers, and use is often delayed or eventually abandoned as a treatment option. We tested the hypothesis that acute coronary syndromes, coronary interventions, stroke, and cardiac arrest are more prevalent in patients with rejected or abandoned PCSK9i prescriptions than for those with paid PCSK9i prescriptions.

eCardio Hub Collection
General CV
Kelly D. Myers , Niloofar Farboodi, Mkaya Mwamburi, William Howard, David Staszak, Samuel Gidding, Seth J. Baum, Katherine Wilemon, Daniel J. Rader